How Dendreon's drug Provenge performs in sequence with Johnson & Johnson's drug Zytiga to treat advanced stage prostate cancer is crucial to the company's near- to mid-term success. In this video, Motley Fool health care analyst David Williamson discusses the possible outcomes and how Dendreon will move forward if the clinical trial is a failure.
While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. Make sure you start 2013 with a bang and get the inside scoop on what Motley Fool Superinvestor David Gardner will be buying this year. He's crushed the market in his Stock Advisor and Rule Breakers portfolios for years, and now we invite you to a personal tour of his flagship stock-picking service: Supernova. Just click here now for instant access.
The article Dendreon's Critical Clinical Trials originally appeared on Fool.com.David Williamson and Max Macaluso haveno position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Dendreon and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.